AbbVie has launched Boey in Europe, a botulinum toxin formulation engineered for faster onset compared to Botox. The product represents a differentiated entry point in a market where onset speed—traditionally 3–7 days for standard toxins—has become a competitive lever, particularly among practitioners seeking to reduce patient wait time and improve treatment satisfaction.
Injectables
AbbVie Launches Boey, Rapid-Onset Toxin, in Europe
New neuromodulator formulation targets faster onset; competitive pressure on Botox pricing intensifies.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Faster onset becomes the new competitive battleground.
Boey's European launch signals AbbVie's intent to defend and expand its toxin franchise against rising competition from Galderma's Botox, Revance's Daxxify (which offers 6-month duration), and Korean generics like Nabota and Letybo. For U.S. practices, the question is timing: if Boey gains traction in Europe, FDA submission is likely. Practices should monitor onset claims carefully—faster onset does not equal longer duration, and patient expectations must be managed accordingly.
Source: original report ↗
Frequently asked questions
What is Boey and how does it differ from Botox?
Boey is a botulinum toxin formulation launched by AbbVie in Europe designed for faster onset than traditional Botox. While standard toxins like Botox typically take 3–7 days to show results, Boey's engineering targets reduced onset time, though duration remains comparable to existing products.
When will Boey be available in the United States?
Boey is not yet available in the U.S. However, if the product gains traction in Europe, FDA submission is likely in the coming years. Practices should monitor regulatory announcements for timing on U.S. availability.
Does faster onset mean Boey lasts longer than Botox?
No. Faster onset does not equal longer duration—these are separate properties. Boey's advantage is reduced wait time for results, not extended longevity. Practitioners must clearly communicate this distinction to patients to manage expectations.
How does Boey fit into the competitive toxin market?
Boey addresses rising competition from Galderma's Botox, Revance's Daxxify (6-month duration), and Korean generics like Nabota and Letybo. AbbVie is using faster onset as a differentiation strategy to improve patient satisfaction and reduce treatment intervals.
What should medspa owners know about Boey's competitive advantage?
Onset speed has become a key competitive lever in the toxin market. Boey's faster results can reduce patient wait time and improve satisfaction, but practices should avoid overpromising duration or results. Careful patient education on realistic timelines remains essential.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.